Company / Depreciation & Amortization
Gilead Sciences Depreciation & Amortization History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$329.0M
FY2023
5-year range
$255.0M / $329.0M
FY2019-FY2023
Trend
+14.2%
vs FY2022
Sector context
#14 of 168
Health Care
What the data says
Among 168 Health Care companies, Gilead Sciences is in the bottom 8% for depreciation & amortization. Depreciation & Amortization has increased for 6 consecutive years, from $125M in FY2016 to $329M in FY2023.
Based on SEC 10-K filings.
$329M in FY2023 with a 5-year CAGR of +13.2%. Top quartile in the Health Care sector.
Increased from $255M to $329M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +13.2%
- 10-Year CAGR
- -
Sector benchmark
+54.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +13.2%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 14.2% year-over-year.
- Ranks #14 out of 168 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $329.0M | +14.2% |
| FY2022 | $288.0M | +12.9% |
| FY2021 | $255.0M | - |
| FY2020 | - | - |
| FY2019 | $233.0M | +31.6% |
| FY2018 | $177.0M | +9.9% |
| FY2017 | $161.0M | +28.8% |
| FY2016 | $125.0M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026